News & Events
On April 16, the heart of Rouen beat to the rhythm of prevention. On the forecourt of the Cathedral, the Alain Cribier Institute, together with Rouen University Hospital and Alliance du Cœur, transformed a complex public health issue into a unique human and educational experience.
A look back at a record-breaking day that reflects the very purpose of our Institute: medical excellence for all.
Professor Alain Cribier (1945–2024) is universally recognized as one of the greatest innovators in modern cardiology. His name is inseparable from a major medical revolution: the development of percutaneous treatment for heart valve disease, and in particular transcatheter aortic valve implantation, known as TAVI.
The Alain Cribier Institute was born from an exceptional medical history, but also from a shared determination to structure and extend a unique legacy in the field of heart valve disease.
On Wednesday, April 1, 2026, Professor Hélène Eltchaninoff, Head of Cardiology at Rouen University Hospital, received the Danièle-Hermann Prize at the Palais de l’Institut de France. Awarded by the Cardiovascular Research Foundation (Institut de France), the prize includes €30,000 and recognizes a career dedicated to medical innovation and research in cardiovascular disease, particularly heart valve disease.
A Public Health Emergency… Still Too Silent
Heart valve disease is increasing as the population ages. Today, nearly 30 million people worldwide are estimated to be living with heart valve disease, a number that could double by 2050. In Europe, more than 10% of people over age 75 are believed to have moderate to severe valve disease.